Gelsyn-3
Ibsa Institut Biochimique SA · Decision date Jul 24, 2026
What did the FDA decide?
FDA records P110005/S015 as a supplement to PMA P110005, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 24, 2026.
FDA approval order statement
Approved for the addition of a new dispensing area, Room A107, for the sampling and weighing of raw materials used in the manufacture of GELSYN-3 (sodium hyaluronate 0.84%) at the IBSA Farmaceutici Italia Srl facility in San Grato-Lodi, Italy, under the same FEI as the currently approved dispensing area
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Orthopedic
- Decision date
- Jul 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P110005/S015
- Regulatory pathway
- PMA supplement
- Applicant
- Ibsa Institut Biochimique SA
- Product code
- MOZ
- Decision code
- OK30
- Decision date
- Jul 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Acid, hyaluronic, intraarticular.
- Applicant
- Ibsa Institut Biochimique SA
- Product code
- MOZ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P110005/S015 received
Application receipt date recorded by FDA.
P110005/S015 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P110005. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code MOZ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Gel-OneP080020/S056 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
SUPARTZ FXP980044/S067 | Seikagaku Corp. | PMA supplement | Sep 4, 2026 | FDA |
EUFLEXXA (1% sodium hyaluronate)P010029/S043 | Ferring Pharmaceuticals, Inc. | PMA supplement | Sep 2, 2026 | FDA |
Orthovisc Injectable Intra-Articular DevicesP030019/S028 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
GEL-ONEP080020/S057 | Seikagaku Corp. | PMA supplement | Aug 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Ibsa Institut Biochimique SA
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Via Al Ponte 13, Ch-6903, Lugano Ticino, 6903
Sources and methodology
- Original FDA record: P110005/S015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


